{"schema_version":"1.0","type":"article","title":"22 億美元，買下一個自體免疫藥王？","url":"https://drugnews.com.tw/articles/2026-08-07-argenx-forte-fb102-acquisition.html","markdown_url":"https://drugnews.com.tw/articles/2026-08-07-argenx-forte-fb102-acquisition.md","lang":"zh-Hant","date":"2026-08-07","publish_at":"2026-08-07T08:00:00+08:00","updated_at":"2026-08-07","category":"商業分析系列","topic":"商業分析系列","tags":["argenx","Forte Biosciences","FB102","VYVGART","CD122","自體免疫","白斑","乳糜瀉","健喬","安立璽榮","安成生技"],"summary":"argenx 擬以 22 億美元現金收購 Forte，把早期抗 CD122 抗體 FB102 納入管線。真正的考題不是一組一期 p 值，而是 VYVGART 的單品成功能否被複製成可重複的公司能力。","key_points":[],"facts":[],"sections":["01｜交易還沒完成，價格已先把期待買滿","02｜VYVGART 給了 argenx 一張昂貴的入場券","03｜先改正一個關鍵：FB102 切的是 IL-2／IL-15","04｜兩個一期訊號，值不值得 22 億美元？","05｜故事夠大，三道風險仍得過關","06｜台灣不是沒有角色，但不能亂湊「概念股」","結語｜VYVGART 證明會做大；FB102 要證明能再做一次","參考資料"],"references":[{"title":"argenx，2026/07/27 收購 Forte 公告","source":"","date":"","url":""},{"title":"https://argenx.com/news/2026/press-release-3333257.html","source":"","date":"","url":"https://argenx.com/news/2026/press-release-3333257.html"},{"title":"Forte Biosciences，2026/07/27 Form 8-K 與合併協議","source":"","date":"","url":""},{"title":"https://www.sec.gov/Archives/edgar/data/1419041/000119312526316766/d31466d8k.htm","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1419041/000119312526316766/d31466d8k.htm"},{"title":"argenx，2026 年上半年財務與第二季營運更新","source":"","date":"","url":""},{"title":"https://argenx.com/news/2026/press-release-3331862.html","source":"","date":"","url":"https://argenx.com/news/2026/press-release-3331862.html"},{"title":"Forte Biosciences，FB102 乳糜瀉 Phase 1b 結果","source":"","date":"","url":""},{"title":"https://www.fortebiorx.com/investor-relations/news/news-details/2025/Forte-Biosciences-Announces-Positive-Data-in-FB102-Celiac-Disease-Phase-1B-Study/default.aspx","source":"","date":"","url":"https://www.fortebiorx.com/investor-relations/news/news-details/2025/Forte-Biosciences-Announces-Positive-Data-in-FB102-Celiac-Disease-Phase-1B-Study/default.aspx"},{"title":"Forte Biosciences，FB102 白斑 Phase 1b 結果","source":"","date":"","url":""},{"title":"https://www.fortebiorx.com/investor-relations/news/news-details/2026/FB102-Achieves-Statistically-Significant-Improvement-in-Vitiligo-at-Week-24-After-Completion-of-12-Week-Treatment-Period/default.aspx","source":"","date":"","url":"https://www.fortebiorx.com/investor-relations/news/news-details/2026/FB102-Achieves-Statistically-Significant-Improvement-in-Vitiligo-at-Week-24-After-Completion-of-12-Week-Treatment-Period/default.aspx"},{"title":"ClinicalTrials.gov，乳糜瀉 Phase 2（NCT06982963","source":"","date":"","url":""},{"title":"https://clinicaltrials.gov/study/NCT06982963","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06982963"},{"title":"ClinicalTrials.gov，白斑 Phase 1（NCT06905873","source":"","date":"","url":""},{"title":"https://clinicaltrials.gov/study/NCT06905873","source":"","date":"","url":"https://clinicaltrials.gov/study/NCT06905873"},{"title":"argenx／再鼎醫藥大中華區合作公告","source":"","date":"","url":""},{"title":"https://argenx.com/news/2021/argenx-and-zai-lab-announce-strategic-collaboration-efgartigimod-greater-china","source":"","date":"","url":"https://argenx.com/news/2021/argenx-and-zai-lab-announce-strategic-collaboration-efgartigimod-greater-china"},{"title":"健喬 2026 年第一季法人說明會、安立璽榮與安成生技官方管線資料。","source":"","date":"","url":""},{"title":"#argenx #Forte #FB102 #VYVGART #CD122 #自體免疫 #白斑 #乳糜瀉 #健喬 #安立璽榮 #安成生技 #藥時事","source":"","date":"","url":""},{"title":"免責聲明：本文為生技醫藥與產業趨勢整理，不構成醫療診斷、治療建議或投資建議。藥物研發、監管審查、交易交割與商業化均具有不確定性，實際判斷應以官方最新資料與專業意見為準。","source":"","date":"","url":""}],"images":[{"alt":"argenx 以 22 億美元收購 Forte、把 FB102 納入免疫管線的交易考題","url":"https://drugnews.com.tw/assets/articles/argenx-forte-fb102-acquisition/figure-01.png"},{"alt":"VYVGART 現金流如何支撐 argenx 收購 FB102","url":"https://drugnews.com.tw/assets/articles/argenx-forte-fb102-acquisition/figure-02.png"},{"alt":"FB102 的 CD122、IL-2 與 IL-15 作用邊界","url":"https://drugnews.com.tw/assets/articles/argenx-forte-fb102-acquisition/figure-03.png"},{"alt":"FB102 從兩組 Phase 1b 訊號走向 Phase 2 與長期安全驗證的證據階梯","url":"https://drugnews.com.tw/assets/articles/argenx-forte-fb102-acquisition/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/argenx-forte-fb102-acquisition/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-08-07）。22 億美元，買下一個自體免疫藥王？。https://drugnews.com.tw/articles/2026-08-07-argenx-forte-fb102-acquisition.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-08-07-argenx-forte-fb102-acquisition-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}